{
  "docId": "019de076-48c2-7315-bf77-72d2721572a4",
  "docSlug": "9ba2b11c98152a86fe4ad3555ff50f91",
  "documentTitle": "Immatics | Investor Presentation Deck | 75 slides",
  "authorId": "immatics",
  "authorName": "Immatics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 42,
  "pageCount": 75,
  "prevPage": 41,
  "nextPage": 43,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide outlines a manufacturing process for off-the-shelf cell therapy.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-48c2-7315-bf77-72d2721572a4/42",
  "deckHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4",
  "deckJsonHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4.json",
  "deckAnchorHref": "/decks/019de076-48c2-7315-bf77-72d2721572a4#slide-42",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.9,
        "x": 0.05,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Workflow from donor collection to patient treatment",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04067791-abcb-4d28-9a9e-cc6d2b805182",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "Off-the-shelf cell therapy, no need for personalized manufacturing -> reduced logistics and time to application. Potential for hundreds of doses from one single donor leukapheresis -> lower cost of goods. Use of healthy donor material provides standardized quality.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eaf18366-df89-4ef5-a887-541b2346a502",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Strategic collaborations combining Immatics’ proprietary ACTallo® platform with Bristol Myers Squibb’s next-gen technologies and Editas Medicine’s CRISPR gene editing technology to develop next-gen allogeneic γδ TCR-T/CAR-T programs",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e033d752-42c4-41f2-990b-9320e9dfef46",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "ACTallo® – Immatics’ Allogeneic Cell Therapy Approach",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d3b690c-9458-4477-9041-702a84b4f056",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "f784899d-04a3-462d-9b86-b80cdccf3a1a",
      "evidence": "The slide uses a linear flow diagram to explain the manufacturing steps.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}